Abstracts tagged "Biologic drugs"

Abstract Number: 1451 • 2017 ACR/ARHP Annual Meeting
Starting of Biological Dmards May be Postponed in RA Patients with Multimorbidity: Single Centre Real Life Results
Berkan Armagan¹, Alper Sari¹, Abdulsamet Erden¹, Levent Kilic¹, Efe Cem Erdat², Omer Karadag³, Ali Akdogan¹, Sule Apras Bilgen³, Ihsan Ertenli³, Sedat Kiraz¹ and Umut Kalyoncu^1,3, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: RA is a burdensome for most of the patients, comorbidities usually provide additional disadvantags the course of RA. The possible effects of comorbidities on…
Abstract Number: 27 • 2017 ACR/ARHP Annual Meeting
Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab
Roberta Fenoglio¹, Laura Solfietti¹, Savino Sciascia² and Dario Roccatello¹, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Monoclonal antibodies (MoAbs) are highly successful in treating various immunological disorders. The development of anti-drug antibodies (ADA) against the therapeutic MoAb is relatively common.…
Abstract Number: 1455 • 2017 ACR/ARHP Annual Meeting
Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio Registry
Nevsun Inanc¹, Zeynep Erturk¹, Gulsen Ozen¹, Ediz Dalkilic², Suleyman Serdar Koca³, Gerçek Can⁴, Ahmet Karatas⁵, Yavuz Pehlivan⁶, Ayten Yazici⁷, Ayse Cefle⁷, Servet Akar⁸, Soner Senel⁹, Burak Oz³, Nurullah Akkoc¹⁰, Haner Direskeneli¹ and Fatos Onen¹¹, ¹Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁵Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁶Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁷Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ⁸Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁹Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹⁰Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: TURKBIO is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011.In 2016,the EULAR RA management guideline recommended assessment of…
Abstract Number: 196 • 2017 ACR/ARHP Annual Meeting
Patient Assistance Program Outcomes in a Community Clinic Setting
Stephanie Cerritos¹, Yanira Ruiz-Perdomo¹, Natalie Tobar¹, Ann Biehl² and James D. Katz³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD
Background/Purpose: Uninsured rheumatic disease patients are at risk for inadequate treatment due to issues with access to care, such as medication costs that average at…
Abstract Number: 1478 • 2017 ACR/ARHP Annual Meeting
Inadequate Clinical Response to Sirukumab, an Anti-IL-6 Monoclonal Antibody, Can be Predicted after a Single Dose of Treatment in Patients with Rheumatoid Arthritis
Shruti Daga¹, Daniel Aletaha², Benjamin Hsu³, Jennifer Gilbride⁴, Jacquie Christie⁵, Matthew Loza³, Bidisha Dasgupta³, Kim Campbell³, Kurt Brown⁶, Ravi Rao⁵ and Paul P. Tak⁵, ¹GlaxoSmithKline, Uxbridge, United Kingdom, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Sum of Squares Ltd, Hertfordshire, United Kingdom, ⁵GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ⁶GlaxoSmithKline, Collegeville, PA
Background/Purpose: Response to therapy in rheumatoid arthritis (RA) is heterogeneous. Early identification of patients (pts) who are unlikely to achieve a meaningful clinical response may…
Abstract Number: 238 • 2017 ACR/ARHP Annual Meeting
Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors
Ayako Nishino^1,2,3, Shinya Kawashiri^2,3, Tamami Yoshitama², Nobutaka Eiraku², Naoki Matsuoka², Yukitaka Ueki², Akitomo Okada², Hiroaki Hamada², Toshihiko Hidaka², Shuji Nagano², Tomomi Tsuru², Keita Fujikawa², Yojiro Arinobu², Yoshifumi Tada², Yasuhiro Nagata¹ and Atsushi Kawakami^2,4, ¹Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan
Background/Purpose: Efficacy of cycling of TNF inhibitors, judged by composite measures, is inferior to non-TNF biologics in patients with RA inadequate response to previous TNF…
Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Julianna Hirsch¹, Michal Nudel², Shira Ginsburg³, Haya Hussein³, Karina Zilber³, Lisa Kaly³, Doron Rimar³, Nina Boulman³, Abid Awisat³, Hily Wollach², Michael Rozenbaum³, Itzhak Rosner³ and Gleb Slobodin³, ¹Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Haifa, Israel, ²Mifrakim Tz'eirim, Haifa, Israel, ³Bnai-Zion Medical Center, Haifa, Israel
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…
Abstract Number: 280 • 2017 ACR/ARHP Annual Meeting
Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Maria Chiara Ditto¹, Alberto Batticciotto¹, Maria Chiara Gerardi¹, Federica Rigamonti², Rossella Talotta¹ and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy
Background/Purpose: immunosuppressive therapies and bDAMRDs expecially, increase the risk of infections. According to the EULAR guidelines, all patients affected by autoimmune/inflammatory diseases should receive vaccinations…
Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Birju D. Bhatt¹, J. Lynn Palmer², Jeffrey R. Curtis³, Sathya Velkuru⁴ and Joel Kremer⁵, ¹Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, ²Corrona Research Foundation, Albany, NY, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, Albany Medical College, Albany, NY, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting
Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity
Nathan den Broeder¹, Lieke Tweehuysen¹, Noortje van Herwaarden¹, Thomas Vogl², F.H.J. van den Hoogen¹, Rogier Thurlings³ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²University of Muenster, Muenster, Germany, ³Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…
Abstract Number: 1908 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
Carter Thorne¹, Tsutomu Takeuchi², George Karpouzas³, Shihong Sheng⁴, Regina Kurrasch⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto, Newmarket, ON, Canada, ²Keio University Hospital School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) despite DMARD treatment, sirukumab, a human monoclonal antibody that selectively binds to the IL-6 cytokine with…
Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting
No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients
Lieke Tweehuysen¹, Nathan den Broeder¹, Leo .A.B. Joosten², Thomas Vogl³, F.H.J. van den Hoogen⁴, Rogier Thurlings⁵ and Alfons A Den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ³University of Muenster, Muenster, Germany, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Rheumatology, Radboudumc, Nijmegen, Netherlands
Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…
Abstract Number: 2284 • 2017 ACR/ARHP Annual Meeting
Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Carlos Sánchez-Piedra¹, Rosa Rosello², Javier Manero³, M. Victoria Hernández⁴, Fernando Sánchez-Alonso⁵, Eduardo Cuende⁶, Blanca García Magallon³, Ana M. Ortiz Garcia⁷, Cesar Diaz-Torné⁸, Mercedes Freire⁹, Paloma Vela¹⁰, Raúl Menor Almagro¹¹, Agueda Prior¹², Federico Díaz-González¹³, Juan J. Gomez-Reino¹⁴ and Sagrario Bustabad¹⁵, ¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²Hospital San Jorge, Huesca, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁶University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ⁷Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁸GEACSER, Madrid, Spain, ⁹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁰Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ¹¹Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹²Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹³Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁴Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ¹⁵Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The advent of new biological drugs has changed the prognosis and…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 2529 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Marina Machado¹, Cristiano S. Moura², Hassan Behlouli¹, Jeffrey R. Curtis³ and Sasha Bernatsky⁴, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor approved in the USA in November 2012 for the treatment of rheumatoid arthritis (RA). As the…

« Previous Page
1
…
4
5
6
7
8
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.